An Act establishing a commission to study maximum allowable costs lists

This bill establishes a special commission to investigate how health plans and pharmaceutical benefit managers use "maximum allowable cost" lists to determine the highest price they will pay for prescription drugs. The commission will consist of ten members representing government officials, health plans, pharmacists, and advocates for providers, pharmaceutical companies, and benefit managers. Its primary task is to examine current practices, financial impacts, industry standards, and transparency regarding these pricing lists. Within 180 days of passing, the commission must submit a report with its findings and any proposed legislation to relevant state committees.